

15 September 2026

ASX Announcement

## Notice of Annual General Meeting and Closing Date for Director Nominations

---

**Firebrick Pharma Limited** (ASX: FRE) (the **Company** or **Firebrick**) advises that the Company's Annual General Meeting (**AGM**) is scheduled to be convened at 11.00am (AEDT) on Wednesday, 11 November 2026.

The AGM will be held as a virtual meeting through an online meeting platform powered by Automic, where Shareholders will be able to watch, listen, and vote online.

In accordance with the Company's Constitution, the closing date for receipt of director nominations to the Company from persons wishing to be considered for election as a director, is Wednesday, 23 September 2026. Any nominations must be received in writing at the Company's registered office by 5.00pm (AEDT).

The AGM materials will be produced and provided to shareholders in due course.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

### About Firebrick Pharma

Firebrick Pharma is developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its first product, Nasodine<sup>®</sup> Nasal Spray (0.5% PVP-I), has been introduced into the United States, Singapore, and Fiji. Nasodine Nasal Spray was also recently approved for marketing in Indonesia, and the Company is pursuing approval in the Philippines and other markets. Nasodine<sup>®</sup> Throat Spray is the first follow-on product in the Nasodine range and is now available in Singapore and Fiji. Firebrick recently announced plans for a total of up to four products in the Nasodine range and expansion of sales to up to 10 markets over three years. For further information, visit [firebrickpharma.com](https://firebrickpharma.com)

### Contacts:

**Media contact:**

Matthew Wright, NWR Communications  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

**Shareholder Company contact:**

Kam Watson, Firebrick Pharma  
[investors@firebrickpharma.com](mailto:investors@firebrickpharma.com)